SAN DIEGO, Oct. 31 Anadys Pharmaceuticals, Inc.(Nasdaq: ANDS) announced today that it will present at the Acumen BioFin(TM)Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, 2007,at 4:25 p.m. EST (1:25 p.m. PST). The conference is being held at the NewYork Palace Hotel.
Steve Worland, Ph.D., President and Chief Executive Officer of AnadysPharmaceuticals, Inc. will present an overview of Anadys and its twodevelopment-stage product candidates, ANA598 and ANA773.
The presentation will be simultaneously webcast and can be accessed on theInvestor Relations page of the Company's website athttp://www.anadyspharma.com. Listeners are encouraged to visit the websiteapproximately five minutes prior to the corporate presentation to download orinstall any necessary software. A replay of the presentation will beavailable approximately one hour after the live webcast concludes and will beavailable through November 20, 2007.
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated toimproving patient care by developing novel medicines in the areas of hepatitisC and oncology. The Company is developing ANA598, a small-molecule,non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitisC virus (HCV) infection and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical innature constitute "forward-looking statements." Such statements include, butare not limited to, references to Anadys' strategy, development programs, andability to develop novel small molecule medicines in the areas of hepatitis Cand cancer. Such forward-looking statements involve known and unknown risks,uncertainties and other factors, which may cause Anadys' actual results to bematerially different from historical results or from any results expressed orimplied by such forward-looking statements. For example, the results ofpreclinical studies may not be predictive of future results, and Anadys cannotprovide any assurances that any of its product candidates will not haveunforeseen safety issues, will have favorable results in future clinicaltrials or will receive regulatory approval. Risk factors that may causeactual results to differ are discussed in Anadys' SEC filings, includingAnadys' Form 10-K for the year ended December 31, 2006 and the "Risk Factors"section of Anadys' Form 10-Q for the quarter ended June 30, 2007. Allforward-looking statements are qualified in their entirety by this cautionarystatement. Anadys is providing this information as of this date and does notundertake any obligation to update any forward-looking statements contained inthis document as a result of new information, future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.